EAACI encourages tackling allergic diseases and asthma at their root, and key to this was the Novartis company-sponsored virtual symposium ‘Breakthrough in the understanding of the anti-IgE pathway in CSU’, co-chaired by Professor Marcus Maurer and PD Dr. Alexander Eggel.
Professor Maurer begins with an introduction to chronic spontaneous urticaria (CSU) and then hands over to Dr Alexander Eggel who speaks in detail about IgE inhibition in CSU, explaining why not all anti-IgEs are born equal. Professor Maurer then describes the clinical implications of this inequality which helps to explain the differential effects of omalizumab and ligelizumab in CSU and asthma.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority. This content has been developed in collaboration with Novartis Pharma AG. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.